BioSpace News Archive

Business

Invuity Announces 2017 Fourth Quarter, Full Year Financial Results and Conference Call Date

The Company will host a conference call with the investment community at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time on Tuesday, February 13, 2018.

January 31, 2018
·
1 min read
Drug Development

BriaCell Update: Early Evidence of Efficacy and Safety of Bria-IMT

The company is pleased to provide a further update on its ongoing clinical trial of Bria-IM.

January 31, 2018
·
7 min read
MedXperience: Organizing Committee Welcomes 24 European Delegations to Program Unveiling

On January 22, twenty-four delegations from a number of European countries joined the organizing committee.

January 31, 2018
·
3 min read
Business

Nanollose Ltd Quarterly Update

Nanollose is pleased to provide its Appendix 4C Cashflow Statement for the quarter ended 31 December 2017, together with the following operational update.

January 31, 2018
·
4 min read
INSIGHTEC Closes $150M Series E Financing

Koch Disruptive Technologies led the round with a $100 million investment.

January 31, 2018
·
2 min read
Lone Star Bio

Amid Rapid Growth, QuVa Pharma Announces New Equity and Debt Funding

QuVa Pharma today announced it has raised additional debt and equity funding of up to $40M to support business growth initiatives.

January 31, 2018
·
3 min read
Deals

CAS Group Announces Glass Lewis Recommendation That Aviragen Stockholders Vote AGAINST Merger and Emphasizes Value of Teslexivir (BTA074) Program

CAS Group Supports the BTA074 Program and Considers it a Valuable Asset of Aviragen.

January 31, 2018
·
14 min read
Business

SkylineDx Inks Joint Development Agreement with Mayo Clinic to Develop Diagnostic Tests for Melanoma

For SkylineDx, the collaboration with the renowned Mayo Clinic is an important milestone as it allows the company to develop new diagnostic tests and extend its product offering for a broader group of patients and clinicians.

January 31, 2018
·
3 min read
Business

Camber Spine Reports Strong Performance Results for 2017

2017 was by all accounts a very strong year for Camber Spine with 54.2% growth in Q4 and 46% year-over-year growth largely driven by an increase of 97% of active surgeon users in the past 12 months.

January 31, 2018
·
1 min read
Genetown

Juniper Pharmaceuticals to Explore Strategic Alternatives

The Company has engaged Rothschild as its independent financial advisor to assist Juniper and its Board of Directors in evaluating potential strategic alternatives.

January 31, 2018
·
4 min read